Serum neurofilament light chain predicts long term clinical outcomes in multiple sclerosis

Abstract Serum neurofilament light chain (NfL) is emerging as an important biomarker in multiple sclerosis (MS). Our objective was to evaluate the prognostic value of serum NfL levels obtained close to the time of MS onset with long-term clinical outcomes. In this prospective cohort study, we identi...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Simon Thebault, Mohammad Abdoli, Seyed-Mohammad Fereshtehnejad, Daniel Tessier, Vincent Tabard-Cossa, Mark S. Freedman
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2020
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/dc8ebacfb861461997465aea745bc483
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:dc8ebacfb861461997465aea745bc483
record_format	dspace
spelling	oai:doaj.org-article:dc8ebacfb861461997465aea745bc4832021-12-02T17:45:12ZSerum neurofilament light chain predicts long term clinical outcomes in multiple sclerosis10.1038/s41598-020-67504-62045-2322https://doaj.org/article/dc8ebacfb861461997465aea745bc4832020-06-01T00:00:00Zhttps://doi.org/10.1038/s41598-020-67504-6https://doaj.org/toc/2045-2322Abstract Serum neurofilament light chain (NfL) is emerging as an important biomarker in multiple sclerosis (MS). Our objective was to evaluate the prognostic value of serum NfL levels obtained close to the time of MS onset with long-term clinical outcomes. In this prospective cohort study, we identified patients with serum collected within 5 years of first MS symptom onset (baseline) with more than 15 years of routine clinical follow-up. Levels of serum NfL were quantified in patients and matched controls using digital immunoassay (SiMoA HD-1 Analyzer, Quanterix). Sixty-seven patients had a median follow-up of 18.9 years (range 15.0–27.0). The median serum NfL level in patient baseline samples was 10.1 pg/mL, 38.5% higher than median levels in 37 controls (7.26 pg/mL, p = 0.004). Baseline NfL level was most helpful as a sensitive predictive marker to rule out progression; patients with levels less 7.62 pg/mL were 4.3 times less likely to develop an EDSS score of ≥ 4 (p = 0.001) and 7.1 times less likely to develop progressive MS (p = 0.054). Patients with the highest NfL levels (3rd-tertile, > 13.2 pg/mL) progressed most rapidly with an EDSS annual rate of 0.16 (p = 0.004), remaining significant after adjustment for sex, age, and disease-modifying treatment (p = 0.022). This study demonstrates that baseline sNfL is associated with long term clinical disease progression. sNfL may be a sensitive marker of subsequent poor clinical outcomes.Simon ThebaultMohammad AbdoliSeyed-Mohammad FereshtehnejadDaniel TessierVincent Tabard-CossaMark S. FreedmanNature PortfolioarticleMedicineRScienceQENScientific Reports, Vol 10, Iss 1, Pp 1-11 (2020)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Simon Thebault Mohammad Abdoli Seyed-Mohammad Fereshtehnejad Daniel Tessier Vincent Tabard-Cossa Mark S. Freedman Serum neurofilament light chain predicts long term clinical outcomes in multiple sclerosis
description	Abstract Serum neurofilament light chain (NfL) is emerging as an important biomarker in multiple sclerosis (MS). Our objective was to evaluate the prognostic value of serum NfL levels obtained close to the time of MS onset with long-term clinical outcomes. In this prospective cohort study, we identified patients with serum collected within 5 years of first MS symptom onset (baseline) with more than 15 years of routine clinical follow-up. Levels of serum NfL were quantified in patients and matched controls using digital immunoassay (SiMoA HD-1 Analyzer, Quanterix). Sixty-seven patients had a median follow-up of 18.9 years (range 15.0–27.0). The median serum NfL level in patient baseline samples was 10.1 pg/mL, 38.5% higher than median levels in 37 controls (7.26 pg/mL, p = 0.004). Baseline NfL level was most helpful as a sensitive predictive marker to rule out progression; patients with levels less 7.62 pg/mL were 4.3 times less likely to develop an EDSS score of ≥ 4 (p = 0.001) and 7.1 times less likely to develop progressive MS (p = 0.054). Patients with the highest NfL levels (3rd-tertile, > 13.2 pg/mL) progressed most rapidly with an EDSS annual rate of 0.16 (p = 0.004), remaining significant after adjustment for sex, age, and disease-modifying treatment (p = 0.022). This study demonstrates that baseline sNfL is associated with long term clinical disease progression. sNfL may be a sensitive marker of subsequent poor clinical outcomes.
format	article
author	Simon Thebault Mohammad Abdoli Seyed-Mohammad Fereshtehnejad Daniel Tessier Vincent Tabard-Cossa Mark S. Freedman
author_facet	Simon Thebault Mohammad Abdoli Seyed-Mohammad Fereshtehnejad Daniel Tessier Vincent Tabard-Cossa Mark S. Freedman
author_sort	Simon Thebault
title	Serum neurofilament light chain predicts long term clinical outcomes in multiple sclerosis
title_short	Serum neurofilament light chain predicts long term clinical outcomes in multiple sclerosis
title_full	Serum neurofilament light chain predicts long term clinical outcomes in multiple sclerosis
title_fullStr	Serum neurofilament light chain predicts long term clinical outcomes in multiple sclerosis
title_full_unstemmed	Serum neurofilament light chain predicts long term clinical outcomes in multiple sclerosis
title_sort	serum neurofilament light chain predicts long term clinical outcomes in multiple sclerosis
publisher	Nature Portfolio
publishDate	2020
url	https://doaj.org/article/dc8ebacfb861461997465aea745bc483
work_keys_str_mv	AT simonthebault serumneurofilamentlightchainpredictslongtermclinicaloutcomesinmultiplesclerosis AT mohammadabdoli serumneurofilamentlightchainpredictslongtermclinicaloutcomesinmultiplesclerosis AT seyedmohammadfereshtehnejad serumneurofilamentlightchainpredictslongtermclinicaloutcomesinmultiplesclerosis AT danieltessier serumneurofilamentlightchainpredictslongtermclinicaloutcomesinmultiplesclerosis AT vincenttabardcossa serumneurofilamentlightchainpredictslongtermclinicaloutcomesinmultiplesclerosis AT marksfreedman serumneurofilamentlightchainpredictslongtermclinicaloutcomesinmultiplesclerosis
_version_	1718379617206665216

Serum neurofilament light chain predicts long term clinical outcomes in multiple sclerosis

Ejemplares similares